Skip to main content Accessibility help
×
Home

Just say N2O – nitrous oxide misuse: essential information for psychiatrists

  • Rollo J. G. Sheldon (a1), Michael Reid (a2), Frederick Schon (a3) and Norman A. Poole (a4)

Summary

Nitrous oxide (N2O) misuse is widespread in the UK. Although it is well-known that it can cause devastating myeloneuropathy, psychiatric presentations are poorly described. There is little understanding of who it affects, how it presents, its mechanism of action and principles of treatment. We begin this article with a case study. We then review the literature to help psychiatrists understand this area and deal with this increasing problem, and make diagnosis and treatment recommendations. We describe a diagnostic pentad of weakness, numbness, paraesthesia, psychosis and cognitive impairment to alert clinicians to the need to urgently treat these patients. Nitrous oxide misuse is a pending neuropsychiatric emergency requiring urgent treatment with vitamin B12 to prevent potentially irreversible neurological and psychiatric symptoms.

LEARNING OBJECTIVES

After reading this article you will be able to:

  • understand the epidemiological and clinical features of nitrous oxide misuse
  • understand the mechanisms of action of nitrous oxide
  • describe potential treatment options in nitrous oxide misuse.

DECLARATION OF INTEREST

None.

Copyright

Corresponding author

Correspondence Rollo Sheldon, West Brighton Assessment and Treatment Service, Hove Polyclinic, Nevill Avenue, Hove BN3 7HY, UK. Email: rjgsheldon@doctors.org.uk

References

Hide All
Addison, T (1849) Anaemia: disease of the supra-renal capsules. London Medical Gazette, 43: 517–8.
Alderman, CP, Nyfort-Hansen, K (2000) Nitrous oxide abuse in a community setting: case report. Australian Journal of Hospital Pharmacy, 30: 109–10.
Bjelland, I, Tell, GS, Vollset, SE, et al. (2003) Folate, vitamin B12, homocysteine, and the MTHFR 677C→T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Archives of General Psychiatry, 60: 618–26.
Brodsky, L, Zuniga, J (1975) Nitrous oxide: a psychotogenic agent. Comprehensive Psychiatry, 16: 185–8.
Chen, T, Zhong, N, Jiang, H, et al. (2018) Neuropsychiatric symptoms induced by large doses of nitrous oxide inhalation: a case report. Shanghai Archives of Psychiatry, 30: 56–9.
Chin, J, Forzani, B, Chowdhury, N, et al. (2015) Rehabilitation essential in the recovery of multifactorial subacute combined degeneration. Annals of Physical and Rehabilitation Medicine, 58: 190–2.
Cousaert, C, Heylens, G, Audenaert, K (2013) Laughing gas abuse is no joke. An overview of the implications for psychiatric practice. Clinical Neurology and Neurosurgery, 115: 859–62.
Davy, H (1839) The Collected Works of Sir Humphry Davy, Bart. Vol. 3: Researches, Chemical and Philosophical, Chiefly Concerning Nitrous Oxide … and its Respiration) (ed Davy, J). Smith, Elder and Co.
Deana, R, Vincenti, E, Deana, AD (1977) Levels of neurotransmitters in brain of vitamin B12 deficient rats. International Journal for Vitamin and Nutrition Research, 47: 119–22.
Eastley, R, Wilcock, GK, Bucks, RS (2000) Vitamin B12 deficiency in dementia and cognitive impairment: the effects of treatment on neuropsychological function. International Journal of Geriatric Psychiatry, 15: 226–33.
Ehirim, EM, Naughton, DP, Petróczi, A (2018) No laughing matter: presence, consumption trends, drug awareness, and perceptions of ‘hippy crack’ (nitrous oxide) among young adults in England. Frontiers in Psychiatry, 8: 312.
Emmanouil, DE, Quock, RM (2007) Advances in understanding the actions of nitrous oxide. Anesthesia Progress, 54: 918.
Garakani, A, Welch, AK, Jaffe, RJ, et al. (2014) Psychosis and low cyanocobalamin in a patient abusing nitrous oxide and cannabis. Psychosomatics, 55: 715–9.
Garakani, A, Jaffe, RJ, Savla, D, et al. (2016) Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature. American Journal of Addiction, 25: 358–69.
Grigg, JR (1988) Nitrous oxide mood disorder. Journal of Psychoactive Drugs, 20: 449–50.
Gyulai, FE, Firestone, LL, Mintun, MA, et al. (1996) In vivo imaging of human limbic responses to nitrous oxide inhalation. Anesthesia & Analgesia, 83: 291–8.
Harrison, NA, Kopelman, MD (2009) Endocrine diseases and metabolic disorders. In Lishman's Organic Psychiatry: A Textbook of Neuropsychiatry (4th edn) (by David, AS, Fleminger, S, Kopelman, MD, et al. ): 617–88. Wiley-Blackwell.
Hew, A, Lai, E, Radford, E (2018) Nitrous oxide abuse presenting with acute psychosis and peripheral neuropathy. Australian & New Zealand Journal of Psychiatry, 52: 388.
Home Office (2018) Drug Misuse: Findings from the 2017/18 Crime Survey for England and Wales (Statistical Bulletin 14/18). Home Office.
Jevtović-Todorović, V, Todorović, SM, Mennerick, S, et al. (1998) Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nature Medicine, 4: 460–3.
Jevtovic-Todorovic, V, Benshoff, N, Olney, JW (2000) Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. British Journal of Pharmacology, 130(7): 1692–8.
Kaar, SJ, Ferris, J, Waldron, J, et al. (2016) Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. Journal of Psychopharmacology, 30: 395401.
Kale, A, Naphade, N, Sapkale, S, et al. (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Research, 175: 4753.
Kohtala, S, Theilmann, W, Rosenholm, M, et al. (2019) Cortical excitability and activation of TrkB signaling during rebound slow oscillations are critical for rapid antidepressant responses. Molecular Neurobiology, 56: 4163–74.
LaGraize, SC, Borzan, J, Peng, YB, et al. (2006) Selective regulation of pain affect following activation of the opioid anterior cingulate cortex system. Experimental Neurology, 197: 2230.
Langdon, FW (1905) Nervous and mental manifestations of pre-pernicious anemia. JAMA, 45: 1635–8.
Mancke, F, Kaklauskaitė, G, Kollmer, J, et al. (2016) Psychiatric comorbidities in a young man with subacute myelopathy induced by abusive nitrous oxide consumption: a case report. Substance Abuse and Rehabilitation, 7: 155–9.
Nabben, T, Benschop, A, Korf, DJ (2014) Antenne 2013: Trends in Alcohol, Tabak en Drugs bij Jonge Amsterdammers [Antenna 2013: Trends in Alcohol, Tobacco and Drugs in Young Amsterdammers]. Rozenberg.
Nagele, P, Duma, A, Kopec, M, et al. (2015) Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial. Biological Psychiatry, 78: 10–8.
Navratilova, E, Xie, JY, Meske, D, et al. (2015) Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain. Journal of Neuroscience, 35: 7264–71.
Quock, RM, Emmanouil, DE, Vaughn, LK, et al. (1992) Benzodiazepine receptor mediation of behavioral effects of nitrous oxide in mice. Psychopharmacology, 107: 310–4.
Schwartz, RH, Calihan, M (1984) Nitrous oxide: a potentially lethal euphoriant inhalant. American Family Physician, 30: 171–2.
Sethi, NK, Mullin, P, Torgovnick, J, et al. (2006) Nitrous oxide ‘whippit’ abuse presenting with cobalamin responsive psychosis. Journal of Medical Toxicology, 2: 71–4.
Sheldon, RJG (2019) A potentially catastrophic outcome from a false-positive urinary drug screen immunoassay. Journal of Forensic Psychiatry & Psychology, 30: 185–8.
Shulman, R (1967) Psychiatric aspects of pernicious anaemia: a prospective controlled investigation. BMJ, 3: 266–70.
Smith, AD (1960) Megaloblastic madness. BMJ, 2: 1840–5.
Sterman, AB, Coyle, PK (1983) Subacute toxic delirium following nitrous oxide abuse. Archives of Neurology, 40: 446–7.
Tiemeier, H, van Tuijl, HR, Hofman, A, et al. (2002) Vitamin B12, folate and homocysteine in depression: the Rotterdam study. American Journal of Psychiatry, 159: 2099–101.
Van Atta, RE (2004) Cognitive impairment associated with habitual nitrous oxide abuse. Forensic Examiner, 13(4): 36.
van Amsterdam, J, Nabben, T, van den Brink, W (2015) Recreational nitrous oxide use: prevalence and risks. Regulatory Toxicology and Pharmacology, 73: 790–6.
Wong, SL, Harrison, R, Mattman, A, et al. (2014) Nitrous oxide (N2O)-induced acute psychosis. Canadian Journal of Neurological Sciences, 41: 672–4.
Zucker, DK, Livingston, RL, Nakra, R, et al. (1981) B12 deficiency and psychiatric disorders: case report and literature review. Biological Psychiatry, 16: 197205.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Just say N2O – nitrous oxide misuse: essential information for psychiatrists

  • Rollo J. G. Sheldon (a1), Michael Reid (a2), Frederick Schon (a3) and Norman A. Poole (a4)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *